Published on
The Food and Drug Administration (FDA) this week approved 3 COVID-19 vaccines for the upcoming flu season. However, key restrictions that differ from years past include: fewer vaccine options for the youngest pediatric population; and generally no eligibility for those ages 5-64 who are healthy and not high-risk. In addition, FDA revoked emergency use authorizations for the vaccines, which had included a lower-dose option for children ages 6 months to 4 years.
Announcements were posted on Pfizer and Moderna websites.
| Vaccine | FDA Approval for 2025–2026 Season |
| Pfizer – Comirnaty | • Adults 65+ (all) • Ages 5–64 with at least 1 high-risk condition |
| Moderna – Spikevax | • Adults 65+ (all) • Those 6 months–64 years with a high-risk condition |
| Moderna – mNexspike | • Adults 65+ (all) • Ages 12–64 with at least 1 high-risk condition |
COVID Vaccines Approved For 2025-2026 Respiratory Virus Season